Collectively, our results demonstrate that Cytopore I-encapsulated EMCVIns implants are capable of uninterrupted insulin secretion, which may contribute to the reversal of hyperglycemia and the potential achievement of long-term blood glucose homeostasis. Here, INS is linked to Hyperglycemia.